Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q3 FY2022 Earnings Presentation
19 slides from Jubilant Pharmova's earnings presentation, Feb 4, 2022
Slide 1: Financial Results Quarter Ended December 31, 2021
Financial Results Quarter Ended December 31, 2021
Slide 2: Conference Call Details
Conference Call Details Date : February 04, 2022 Time : 05:00 pm IST +91 22 6280 1141 Primary Number +91 22 7115 8042 USA: 1 866 746 2133 UK: 0 808 101 1573 Toll Free Number Singapore: 800 101 2045 Hong Kong: 800 964 448 Replay: Feb 4 to Feb 11, 2022 Dial-in: +91 22 7194 5757/ +91 22 6663 5757 Playb
Slide 3: Chairmen’s Message
Chairmen’s Message Jubilant Pharmova Q3 and 9M FY22 Particulars 1,2 Q3'FY21 Q3'FY22 9M' FY21 9M' FY22 Total Revenue from Operations 1,771 1,311 4,519 4,603 Reported EBITDA 496 200 1,033 923 Reported EBITDA margin (%) 28.0% 15.3% 22.9% 20.1% Profit After Tax 219 51 401 354 PAT margin (%) 12.4% 3.9% 8
Slide 4: Q3'FY22 Results Analysis
4 IBILANT Spence Q3'FY22 Results Analysis
Slide 5: Q3'FY22 Financial Highlights
Q3'FY22 Financial Highlights 1,2 Particulars Q3'FY21 Q3'FY22 YoY (%) Revenue Revenue was at Rs 1,311 Crore versus Rs 1,771 Crore in Q3'FY21 Pharmaceuticals 1,692 1,186 (30%) • Pharmaceuticals revenue at Rs 1,186 Crore as compared to Contract Research and Development Services 79 120 51% Proprietary
Slide 6: Pharmaceuticals Segment Highlights – Q3'FY22 (1/2)
Pharmaceuticals Segment Highlights – Q3'FY22 (1/2) Particulars 1,2 Q3'FY21 Q3'FY22 YoY (%) Pharmaceuticals revenue at Rs 1,186 Crore vs. Rs 1,692 Crore in Revenue 1,692 1,186 (30%) Q3’FY21 Specialty Pharma 582 633 9% Specialty Pharmaceuticals3 CDMO 650 373 (43%) Generics 460 181 (61%) • Radiopharm
Slide 7: Pharmaceuticals Segment Highlights – Q3'FY22 (2/2)
Pharmaceuticals Segment Highlights – Q3'FY22 (2/2) USFDA Inspection Details CDMO1 Facility Last Inspection • CMO business revenue was affected as revenue related to COVID related one-off Montreal, Radiopharma Sep, 2017 deals tapered off and also because of customer scheduling Montreal, CMO May, 2018
Slide 8: Contract Research and Development Services – Q3'FY22
Contract Research and Development Services – Q3'FY22 Q3'FY21 Q3'FY22 YoY (%) Contract Research and Development Services business through Particulars1,2 Jubilant Biosys Limited provides innovative and collaborative Revenue 79 120 51% research and development services from world class research Repor
Slide 9: Jubilant Therapeutics: Developing best-in-class precision therapies in oncology and autoimmune diseases
Jubilant Therapeutics: Developing best-in-class precision therapies to address significant unmet medical needs in oncology and autoimmune diseases 88
Slide 10: Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases
Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases 99
Slide 11: 9M'FY22 Results Analysis
9M'FY22 Results Analysis 10 10
Slide 12: 9M'FY22 Financial Highlights
9M'FY22 Financial Highlights 9M' 9M' YoY (%) Revenue was Rs 4,603 Crore versus Rs 4,519 Crore in 9M'FY21 Particulars1,2 FY21 FY22 Revenue • Pharmaceuticals revenue at Rs 4,271 Crore as compared to Rs Pharmaceuticals 4,304 4,271 (1%) 4,304 Crore in 9M'FY21 Contract Research and Development Services
Slide 13: Pharmaceuticals Segment Highlights – 9M'FY22
Pharmaceuticals Segment Highlights – 9M'FY22 Geography Wise Revenue 9M' 9M' 9M' 9M' Particulars1,2 YoY (%) Particulars YoY (%) FY21 FY22 FY21 FY22 Revenue 4,304 4,271 (1%) India 220 266 21% Specialty Pharma 1,701 1,917 13% North America 3,395 3,465 2% CDMO 1,435 1,409 (2%) Europe and Japan 330 234 (
Slide 14: Contract Research and Development Services – 9M'FY22
Contract Research and Development Services – 9M'FY22 9M' 9M' Contract Research and Development Services business through Particulars1,2 YoY (%) FY21 FY22 Jubilant Biosys Limited provides innovative and collaborative Revenue 211 315 49% research and development services from world class research Re
Slide 15: Debt Profile
Debt Profile Particulars1 31-03-21 30-06-21 30-09-21 31-12-21 Gross Debt Long Term 2,580 2,630 2,635 2,825 Short Term 20 0 91 33 Total 2,600 2,630 2,726 2,859 Cash & Equivalent 671 937 863 1,022 Net Debt (On a Constant Currency Basis) 1,928 1,651 1,823 1,792 Net Debt (constant currency) reduction
Slide 16: Business outlook
Business outlook Pharma: In radiopharma, we continue to build a long term pipeline of diagnostic and therapeutic radiopharmaceuticals and are executing a turnaround plan of radiopharmacies. Medium-long term outlook remains robust. Allergy business well placed to grow strongly with healthy margins
Slide 17: Appendix
a Es ¥ oa (o) VA A p pend IX 16
Slide 18: Income Statement – Q3 & 9M FY22
Income Statement – Q3 & 9M FY22 Particulars1,2 Q3'FY21 Q3'FY22 YoY (%) 9M' FY21 9M' FY22 YoY (%) Total Revenue from Continuing Operations Pharmaceuticals 1,692 1,186 (30%) 4,304 4,271 (1%) Contract Research and Development Services 79 120 51% 211 315 49% Proprietary Novel Drugs 0 0 - 4 2 - Unallocab
Slide 19: For more information
For more information For Investors: Vineet V Mayer Siddharth Rangnekar Ph: +91 120 436 1103 CDR India E-mail: vineet.mayer@jubl.com Ph: +91 +91 9769919966 E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1062 Madison Public Relations E-mail: sudhakar.safaya@j